Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Xubao Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1288-7089; OpenAlex author ID A5101951692. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 6 papers · 2024: 1 paper

Papers 20

  1. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/cad.0000000000001545↗
  2. The differential effects of sarcopenia and cachexia on overall survival for pancreatic ductal adenocarcinoma patients following pancreatectomy: A retrospective… Co-author DOI 10.1002/cam4.5779↗
  3. Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. Co-author DOI 10.1016/j.cbi.2023.110546↗
  4. Prognostic role of radiological splenic vessel involvement in patients with resectable pancreatic ductal adenocarcinoma of the body and tail: A retrospective a… Co-author DOI 10.1016/j.ejrad.2023.110952↗
  5. Long Term Outcomes of No-Touch Isolation Principles Applied in Pancreaticoduodenectomy for Treatment of Pancreatic Adenocarcinoma: A Multicenter Retrospective … Co-author DOI 10.3390/jcm12020632↗
  6. Associations between Systemic Immune-Inflammation Index and Diabetes Mellitus Secondary to Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/jcm12030756↗
  7. Elevated Bile Acid Is Associated with Worsened Impaired Glucose Homeostasis in Pancreatic Ductal Adenocarcinoma Patients with Extrahepatic Cholestasis through … Co-author DOI 10.3390/jcm12062352↗
  8. The expression of m6A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.21037/gs-21-859↗
  9. Comment on "Optimal Number of Examined Lymph Node May Dependent on Age in Patients With Pancreatic Adenocarcinoma". Last author DOI 10.1097/sla.0000000000003811↗
  10. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: … Co-author DOI 10.3389/fonc.2021.801320↗
  11. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Co-author DOI 10.1016/j.cdtm.2020.01.002↗
  12. Early recurrence detected by 18F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000019504↗
  13. Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001522↗
  14. Risk of pancreatic cancer in patients undergoing surgery for chronic pancreatitis. Last author DOI 10.1186/s12893-019-0537-1↗
  15. Disparities in survival by stage after surgery between pancreatic head and body/tail in patients with nonmetastatic pancreatic cancer. Last author DOI 10.1371/journal.pone.0226726↗
  16. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Co-author DOI 10.1038/s41598-018-36214-5↗
  17. A case-matched comparison study of total pancreatectomy versus pancreaticoduodenectomy for patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ijsu.2017.10.065↗
  18. dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Stud… Last author DOI 10.1097/md.0000000000002936↗
  19. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Co-author DOI 10.18632/oncotarget.9491↗
  20. Deleted in liver cancer-1 inhibits cell growth and tumorigenicity in human pancreatic cancer. Last author DOI 10.3892/ol.2013.1415↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nengwen Ke · 9 shared papers, 2016–2023 · strength 1.35
  2. Chunlu Tan · 9 shared papers, 2013–2024 · strength 1.35
  3. Yonghua Chen · 6 shared papers, 2019–2024 · strength 1.10
  4. Zhenjiang Zheng · 6 shared papers, 2013–2024 · strength 0.91
  5. Ziyao Wang · 3 shared papers, 2021–2023 · strength 0.53
  6. Yu Mou · 3 shared papers, 2020–2023 · strength 0.46
  7. Qingquan Tan · 2 shared papers, 2023 · strength 0.44
  8. Xing Wang · 2 shared papers, 2023 · strength 0.42
  9. Junjie Xiong · 3 shared papers, 2016–2022 · strength 0.29
  10. Li Mao · 2 shared papers, 2020 · strength 0.23
  11. Haoqi Zhang · 1 shared paper, 2023 · strength 0.22
  12. Yonghua Chen · 1 shared paper, 2023 · strength 0.22
  13. Xing Wang · 1 shared paper, 2023 · strength 0.22
  14. Jie Yang · 1 shared paper, 2023 · strength 0.22
  15. Guanhua Chen · 1 shared paper, 2023 · strength 0.22
  16. Yichen Li · 1 shared paper, 2024 · strength 0.22
  17. Xiaoding Shen · 1 shared paper, 2023 · strength 0.20
  18. Zhenjiang Zheng · 1 shared paper, 2021 · strength 0.19
  19. Chunlu Tan · 1 shared paper, 2021 · strength 0.19
  20. Ang Li · 2 shared papers, 2016–2020 · strength 0.17
  21. Yutong Yao · 1 shared paper, 2022 · strength 0.16
  22. Ji Liu · 1 shared paper, 2023 · strength 0.14
  23. Ruiman Geng · 1 shared paper, 2023 · strength 0.14
  24. Huawei Cai · 1 shared paper, 2023 · strength 0.14
  25. Weiming Hu · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.